. .

 
Zuruecksetzen

Suchergebnis - JOHNSON & JOHNSON REGISTERED SHARES DL 1

Zeit Titel
20.09 14:04dpa-AFX: Janssen-Cilag Reports CHMP Recommendation For Daratumumab
20.09 13:43dpa-AFX: *J&J : DARZALEX QUADRUPLET REGIMEN GETS POSITIVE CHMP OPINION FOR NEWLY DIAGNOSED MYELOMA PATIENTS
20.09 02:47dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy
16.09 09:33dpa-AFX: Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study
16.09 08:55dpa-AFX: *J&J ANNOUNCES INTERIM DATA FROM PHASE 2 SUNRISE-4 STUDY OF TAR-200 COMBINATION IN MUSCLE-INVASIVE BLADDER CANCER
15.09 10:15dpa-AFX: J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer
14.09 16:39dpa-AFX: J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer
14.09 09:54dpa-AFX: J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial
13.09 07:20dpa-AFX: *HSBC RAISES JOHNSON & JOHNSON PRICE TARGET TO 180 (174) USD - 'BUY'
13.09 07:20dpa-AFX: *HSBC HEBT ZIEL FÜR JOHNSON & JOHNSON AUF 180 (174) USD - 'BUY'
12.09 15:49dpa-AFX: Janssen-Cilag Announces First EMA Submission For Nipocalimab
12.09 15:36dpa-AFX: *J&J SEEKS EU APPROVAL FOR NIPOCALIMAB TO TREAT ANTIBODY-POSITIVE GENERALISED MYASTHENIA GRAVIS
12.09 03:01dpa-AFX: J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults
11.09 05:39dpa-AFX: J&J's Dexamethasone Regimen Reduces Infusion Reactions In EGFR-Mutated NSCLC Patients On RYBREVANT
09.09 03:06dpa-AFX: J&J : Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small Cell Lung Cancer
05.09 22:11MÄRKTE USA/Uneinheitlich - Vor Arbeitsmarktbericht steigt Nervosität
05.09 18:02MÄRKTE USA/Börse dreht ins Minus - Zurückhaltung vor Jobdaten
05.09 15:44MÄRKTE USA/Wall Street behauptet zu Handelsbeginn
05.09 15:05MÄRKTE USA/Börsen etwas leichter erwartet - Konjunkturdaten im Blick
05.09 12:30MARKT USA/Zurückhaltung - Konjunkturdaten im Blick

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH